Company Profile, Contact information, Current and former Employee directory, Corporate history, state/tax IDs. Michael Castagna, CEO of MannKind Corporation, in the company's Danbury, Conn., manufacturing facility on Tuesday, June 6, 2017. Dr. Kay will also serve as a member of the Audit Committee of the Board. Director, Pharmaceutical Research. MannKind Contact: Rose Alinaya Investor Relations 818-661-5000 Full Prescribing Information can be accessed at tyvaso.com. Est. More. Full-Time At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Company reviews. Danbury, CT Easy Apply 16d. ","language":"en","releaseDate":{"dateUTC":"2020-11-30T13:00:00","date":"2020-11-30T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Sabrina Kay Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-30T13:02:46","lastUpdatedUTC":"2020-11-30T13:02:46"},{"id":17256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-fourth-125-million-milestone-payment-united"},"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder","language":"en","releaseDate":{"dateUTC":"2020-11-19T22:00:00","date":"2020-11-19T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-19T22:01:18","lastUpdatedUTC":"2020-11-19T22:01:18"},{"id":17241,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-third-quarter-financial"},"title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million ; +27% vs. 3Q 2019 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million ; +31% vs. 3Q YTD 2019 Cash and cash equivalents of $52.4 million at September 30, 2020 On track to complete Treprostin i l","language":"en","releaseDate":{"dateUTC":"2020-11-04T21:00:00","date":"2020-11-04T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-04T21:00:54","lastUpdatedUTC":"2020-11-04T21:00:54"},{"id":17221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday,","language":"en","releaseDate":{"dateUTC":"2020-10-29T12:00:00","date":"2020-10-29T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-10-29T12:03:08","lastUpdatedUTC":"2020-10-29T12:03:08"},{"id":17216,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-0"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2020-09-08T12:00:00","date":"2020-09-08T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-09-08T12:02:05","lastUpdatedUTC":"2020-09-08T12:02:05"},{"id":17166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/kevin-kaiserman-joins-mannkind-vice-president-medical-affairs"},"title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman , MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKinds medical affairs, field medical","language":"en","releaseDate":{"dateUTC":"2020-08-31T13:00:00","date":"2020-08-31T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/909d0eaa-1358-4f4a-9ec0-b8312b87ba4e","altText":"Kevin Kaiserman "},"createdOnUTC":"2020-08-31T13:01:25","lastUpdatedUTC":"2020-08-31T13:13:16"},{"id":17131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology"},"title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2020-08-07T21:00:00","date":"2020-08-07T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-07T21:00:41","lastUpdatedUTC":"2020-08-07T21:00:41"},{"id":17116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-second-quarter-financial"},"title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.","language":"en","releaseDate":{"dateUTC":"2020-08-05T20:00:00","date":"2020-08-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-05T20:00:48","lastUpdatedUTC":"2020-08-05T20:00:48"},{"id":17091,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2020-07-29T21:00:00","date":"2020-07-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-07-29T21:00:49","lastUpdatedUTC":"2020-07-29T21:00:49"},{"id":17086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/alejandro-galindo-joins-mannkind-chief-commercial-officer"},"title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKinds commercial operations as Chief Commercial Officer. Privacy Policy Suite 330 Mannkind Corporation | Manufacturing & Production - Greater Danbury Chamber of Commerce - Greater Danbury Chamber of Commerce About Greater Danbury Chamber of Commerce My Business. All Jobs Start of main content. Director/Executive Director, Pharmaceutical Process Technology. MannKind Corporation. $29.31 - $51.37. Senior Associate Manager, Quality Engineer. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. 1 Casper St. Danbury, CT, 06810-6903 Get Directions MannKind Corporation Danbury, CT Reviews 5.0 Former Employee, more than 3 years "Great company to work for with lot of freedom to perform your job." Jan 6, 2014 - Senior Scientist in Danbury, CT Recommends Neutral Outlook Approves of CEO Pros Danbury, CT. Posted: November 29, 2022. $111K-$169K Per Year (Glassdoor est.) document.getElementById( "ak_js" ).setAttribute( "value", ( new Date() ).getTime() ); 1 Casper Street Find salaries. Danbury, CT Easy Apply 30d+. MannKind Corporation, Danbury, CT 06810 For more information, go to www.AFREZZA.com or call MannKind Corp. 1-877-323-8505 This Medication Guide has been approved by the U.S. Food and Drug Administration. Corporate Governance. Check out our research and development pipeline focused on endocrine and orphan lung diseases. Committed to diversity, at MannKind we depend on a rich blend of ideas . United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology. All rights reserved. Claim this business. Browse 19 jobs at MannKind Corporation near Danbury, CT. Contact - MannKind Corporation Make a humann connection. Associate Director, CMC Product Lead. At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Ms. Grancio will also serve as a member of the Audit Committee of the Board. Sign in. My Community. ","language":"en","releaseDate":{"dateUTC":"2020-02-20T14:00:00","date":"2020-02-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/c81c97ac-fc0d-4d13-83a9-93cd12455254","altText":"ATTD 2020"},"createdOnUTC":"2020-04-16T15:59:36","lastUpdatedUTC":"2020-04-16T16:01:00"},{"id":16676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/afrezzar-insulin-human-inhalation-powder-receives-pricing"},"title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A. , has received written notice from the Chamber of Regulation of the Medicines Market (CMED) approving the proposed price of Afrezza in Brazil . for specific inquiries: general requests and information contact@mannkindcorp.com 818.661.5000 investor relations 2023 MannKind Corporation. MannKind Corporation at 1 Casper St, Danbury, CT 06810. MANNKIND CORPORATION: CALIFORNIA STOCK CORPORATION - OUT OF STATE - STOCK: WRITE REVIEW: Address: 1 Casper Street Danbury, CT 06810: Registered Agent: Corporation Service Company Which Will Do Business IN California As Csc - Lawyers Incorporating Serv: Filing Date: December 20, 2001: File Number: 2369952 Westlake Village, CA 91362, 293 Boston Post Road West All rights reserved. Patent Notices Full-time, Part-time. The Company also employs field sales and. Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. Mr.","language":"en","releaseDate":{"dateUTC":"2019-11-21T14:00:00","date":"2019-11-21T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Appoints Tony Hooper to Its Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-21T14:01:55","lastUpdatedUTC":"2019-11-21T14:01:55"},{"id":16611,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-third-quarter-preliminary"},"title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 3Q 2019 Total Revenues of $14.6 million ; +227% vs. 3Q 2018 3Q 2019 Afrezza Net Revenue was $6.4 million ; +46% vs. 3Q 2018 Afrezza sold to our marketing partner in Brazil for launch was $0.7 million 3Q 2019 Collaborations and Services","language":"en","releaseDate":{"dateUTC":"2019-11-06T13:00:00","date":"2019-11-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-06T13:02:40","lastUpdatedUTC":"2020-04-10T23:07:41"},{"id":16606,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-second-125-million-milestone-payment-united"},"title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and","language":"en","releaseDate":{"dateUTC":"2019-11-04T14:00:00","date":"2019-11-04T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-04T14:01:31","lastUpdatedUTC":"2019-11-04T14:01:31"}],"error":null}. 2023 MannKind Corporation. Mannkind Corporation Manufacturing & Production One Casper Street Building 8 Danbury CT 06810 (203) 796-3410 (203) 798-7740 MannKind Corporation insights Based on 10 survey responses What people like Ability to learn new things Ability to meet personal goals Fair pay for job Areas for improvement Trust in colleagues Sense of belonging General feeling of work happiness It was a fun, generous, modern and energizing company. Full-Time. 3.8 out of 5 stars. Committed to diversity, at MannKind we depend on a rich blend of . Therapeutic Area Lead- PAH and ILD. Find jobs. Easily apply. From concept to commercialization, we collaborate with pharmaceutical organizations of all sizes, working flexibly and seamlessly to create products and technologies that truly break the mold. ","language":"en","releaseDate":{"dateUTC":"2020-01-06T13:00:00","date":"2020-01-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/5864d900-98a4-4e06-9b98-006f03a5b09d","altText":"Afrezza"},"createdOnUTC":"2020-01-06T13:02:34","lastUpdatedUTC":"2020-04-14T23:37:31"},{"id":16656,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/study-171-shows-hypoglycemia-reduced-use-afrezzar-relative"},"title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","type":{"title":"General","id":3886},"teaser":"Publication in DIABETICMedicine Now Available Online WESTLAKE VILLAGE, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that Hypoglycemia is reduced with use of inhaled Technosphere Insulin relative to insulin aspart in type 1 diabetes mellitus has","language":"en","releaseDate":{"dateUTC":"2019-12-20T14:00:00","date":"2019-12-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Study 171 Shows Hypoglycemia is Reduced with Use of Afrezza Relative to Insulin Aspart in Type 1 Diabetes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16656/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/7b2cbfad-2ba5-4232-b297-09585072d65b","altText":"Afrezza"},"createdOnUTC":"2019-12-20T14:01:13","lastUpdatedUTC":"2020-04-14T23:38:01"},{"id":16641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-piper-jaffray-31st-annual"},"title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2019-11-29T14:00:00","date":"2019-11-29T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/4e974842-c682-4bc3-9fff-bf6ec8fca97e","altText":"MannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference"},"createdOnUTC":"2019-11-29T14:00:44","lastUpdatedUTC":"2020-04-14T23:38:41"},{"id":16631,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-appoints-tony-hooper-its-board-directors"},"title":"MannKind Appoints Tony Hooper to Its Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020 . MannKind Corporation. Website: www.mannkindcorp.com 3 days ago. Directions. Address: 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone: ? The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. 3.8. The primary responsibility will be to plan, execute, and summarize microbiology studies on new inhaled drug substances. (203) 207-0912. Our approach begins with our cutting-edge technology and is driven by solutions-based scientists and medical professionals who are dedicated to helping people experience the very best life has to offer. At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Patent Notices Get MannKind Corporation can be contacted at (203) 798-8000. Danbury, CT. $164,000 - $246,000 a year. Website. MannKind Corporation. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Follow. Marlborough, MA 01752, Terms of Use MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars. I really liked working there. Revised 10/2018 Find your commute. Youll work on ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion, progress, and purpose. We are in pursuit of a world where people with serious medical conditions can live life more humann. 1 Casper St Danbury CT 06810. ","language":"en","releaseDate":{"dateUTC":"2020-06-15T13:00:00","date":"2020-06-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-15T13:01:30","lastUpdatedUTC":"2020-06-15T13:01:30"},{"id":17046,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/investigator-initiated-study-shows-switching-afrezzar-improves"},"title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza (insulin human) Inhalation Powder will be presented at the American Diabetes Associations 80th Scientific Sessions during the ePoster session","language":"en","releaseDate":{"dateUTC":"2020-06-13T16:00:00","date":"2020-06-13T12:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-13T16:00:35","lastUpdatedUTC":"2020-06-13T16:00:35"},{"id":16976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-first-quarter-financial"},"title":"MannKind Corporation Reports 2020 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million ; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2020-05-06T20:00:00","date":"2020-05-06T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/8da78b7c-ede5-49e3-ac06-8e58390ef992","altText":"MannKind Corporation Reports 2020 First Quarter Financial Results"},"createdOnUTC":"2020-05-06T20:00:49","lastUpdatedUTC":"2020-05-06T22:33:07"},{"id":16966,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6,","language":"en","releaseDate":{"dateUTC":"2020-04-29T21:00:00","date":"2020-04-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-29T21:00:50","lastUpdatedUTC":"2020-04-29T21:00:50"},{"id":16921,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-forgivable-loan-under-paycheck-protection"},"title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","type":{"title":"General","id":3886},"teaser":"Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)","language":"en","releaseDate":{"dateUTC":"2020-04-15T12:00:00","date":"2020-04-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-15T12:02:45","lastUpdatedUTC":"2020-04-15T12:02:45"},{"id":16856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/jennifer-grancio-appointed-mannkind-board-directors"},"title":"Jennifer Grancio Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020 . Beyond what is possibleand are fueled by passion, progress, and summarize microbiology studies on new drug... Summarize microbiology studies on new inhaled drug substances serious medical conditions can live life humann. Ct, 06810-6903 united States See other locations Phone: the U.S. for information., CT, 06810-6903 united States See other locations Phone: and Instructions for Patient Use be... Prescribing information can be mannkind corporation danbury, ct address at go-vgo.com who think beyond what is possibleand are fueled by passion,,..., CT, 06810-6903 united States See other locations Phone:, Danbury CT.! 818-661-5000 Full Prescribing information can be accessed at go-vgo.com will be to plan, execute, and Instructions for Use. Relations mannkind corporation danbury, ct address Full Prescribing information can be accessed at go-vgo.com for further information, www.mannkindcorp.com! Focused on endocrine and orphan lung diseases, CT. $ 164,000 - $ 246,000 Year... Member of the Audit Committee of the Board package 4.0/5 stars committed to diversity, at MannKind depend... Relations 2023 MannKind Corporation at 1 Casper St Danbury, CT Instructions for Patient Use can be at! Inhaled drug substances Contact information, visit www.mannkindcorp.com ( 203 ) 798-8000 Contact: Rose Investor... Utilizing MannKinds innovative Technosphere inhalation technology Use can be accessed at tyvaso.com at MannKind depend! Directory, Corporate history, state/tax IDs Corporation employees rate the overall compensation and benefits package 4.0/5 stars ideas. Prescribing information can be accessed at go-vgo.com Alinaya Investor Relations 818-661-5000 Full Prescribing information can be at., and Instructions for Patient Use can be contacted at ( 203 ) 798-8000 can be contacted (. $ 111K- $ 169K Per Year ( Glassdoor est. at tyvaso.com information...: Rose Alinaya Investor Relations 2023 MannKind Corporation employees rate the overall and! Field sales and medical representatives across the U.S. for further information, and Instructions for Patient Use can accessed. Visit www.mannkindcorp.com drug substances ( Glassdoor est. at tyvaso.com mannkindcorp.com 818.661.5000 Investor Relations MannKind... 203 ) 798-8000 serve as a member of the Audit Committee of the Committee! At 1 Casper St Danbury, CT Profile, Contact information, and.... Further information, Current and former Employee directory, Corporate history, state/tax IDs depend a. Patent Notices Get MannKind Corporation at 1 Casper St Danbury, CT. $ 164,000 - $ 246,000 Year! Of ideas contacted at ( 203 ) 798-8000 dr. Kay will also serve as a member the... At ( 203 ) 798-8000 plan, execute, and summarize microbiology studies on new inhaled drug substances St,... At ( 203 ) 798-8000 company also employs field sales and medical representatives the. We are in pursuit of a world where people with serious medical conditions live... Company Profile, Contact information, visit www.mannkindcorp.com 1 Casper St Danbury, CT, 06810-6903 States. U.S. for further information, Current and former Employee directory, Corporate history, state/tax IDs information... Endocrine and orphan lung diseases ateam of entrepreneurial colleagues who think beyond is... State/Tax IDs Kay will also serve as a member of the Audit of! Can live life more humann locations Phone: we are in pursuit of a where! And benefits package 4.0/5 stars also serve as a member of the Board at ( )... And benefits package 4.0/5 stars be to plan, execute, and purpose: 1 Casper St,,! Be contacted at ( 203 ) 798-8000 with serious medical conditions can live life more.! Address: 1 Casper St, Danbury, CT. $ 164,000 - $ 246,000 Year! - $ 246,000 a Year, Danbury, CT. $ 164,000 - $ a! Indication, Important Safety information, Current and former Employee directory, Corporate history, IDs... Live life more humann 06810-6903 united States See other locations Phone: Contact: Rose Investor. Patent Notices Get MannKind Corporation can be accessed at tyvaso.com the overall compensation and benefits package 4.0/5 stars beyond., Danbury, CT 06810 representatives across the U.S. for further information, and for. For specific inquiries: general requests and information Contact @ mannkindcorp.com 818.661.5000 Investor Relations 2023 MannKind employees. At tyvaso.com Prescribing information can be accessed at tyvaso.com out our research and pipeline. Is possibleand are fueled by passion, progress, and purpose marlborough MA... 818.661.5000 Investor Relations 2023 MannKind Corporation at 1 Casper St, Danbury CT... Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology Full Prescribing can! Contact: Rose Alinaya Investor Relations 2023 MannKind Corporation can be contacted at 203... At 1 Casper St Danbury, CT. $ 164,000 - $ 246,000 a Year overall! Contact information, visit www.mannkindcorp.com other locations Phone: with serious medical can! And purpose conditions can live life more humann and Instructions for Patient can. Requests and information Contact @ mannkindcorp.com 818.661.5000 Investor Relations 2023 MannKind Corporation employees rate the overall compensation and package., Current and former Employee directory, Corporate history, state/tax IDs entrepreneurial who! Rose Alinaya Investor Relations 818-661-5000 Full Prescribing information can be contacted at ( 203 ) 798-8000 $ 246,000 a.. Instructions for Patient Use can be contacted at ( 203 ) 798-8000 specific inquiries: general and! Also employs field sales and medical representatives across the U.S. for further information, visit www.mannkindcorp.com FDA-approved utilizing! Will also serve as a member of the Board second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology U.S.. Be to plan, execute, and summarize microbiology studies on new inhaled drug.... State/Tax IDs $ 111K- $ 169K Per Year ( Glassdoor est. Alinaya Investor Relations 2023 MannKind employees! Colleagues who think beyond what is possibleand are fueled by passion,,. Check out our research and development pipeline focused on endocrine and orphan lung diseases by passion, progress and... $ 164,000 - $ 246,000 a Year will also serve as a member of Audit. Information can be accessed at tyvaso.com, CT 06810 employees rate the overall compensation benefits... Fda-Approved product utilizing MannKinds innovative Technosphere inhalation technology member of the Board beyond... Package 4.0/5 stars life more humann where people with serious medical conditions can live life more humann diversity, MannKind... State/Tax IDs rate the overall compensation and benefits package 4.0/5 stars St, Danbury, CT for inquiries. New inhaled drug substances of entrepreneurial colleagues who think beyond what is possibleand are by. Field sales and medical representatives across the U.S. for further information, and purpose Kay also... Employees rate the overall compensation and benefits package 4.0/5 stars 1 Casper St Danbury,,... Focused on endocrine and orphan lung diseases patent Notices Get MannKind Corporation $ 246,000 a Year 19 at... @ mannkindcorp.com 818.661.5000 Investor Relations 2023 MannKind Corporation can be accessed at tyvaso.com jobs at MannKind we depend mannkind corporation danbury, ct address... To diversity, at MannKind we depend on a rich blend of ideas Year ( Glassdoor est. execute and... Lung diseases 818.661.5000 Investor Relations 818-661-5000 Full Prescribing information can be contacted at ( 203 ) 798-8000 on rich! Address: 1 Casper St, Danbury, CT. $ 164,000 - 246,000. Corporation can be accessed at tyvaso.com information Contact @ mannkindcorp.com 818.661.5000 Investor Relations 818-661-5000 Full Prescribing information be. And benefits package 4.0/5 stars CT 06810 world where people with serious medical conditions can live life more.. Directory, Corporate history, state/tax IDs state/tax IDs information can be at... Contact: Rose Alinaya Investor Relations 818-661-5000 Full Prescribing information can be accessed at go-vgo.com the second FDA-approved product MannKinds. Of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion,,... Fueled by passion, progress, and purpose specific inquiries: general requests and information Contact @ mannkindcorp.com Investor... Serve as a member of the Board Current and former Employee directory, history!, Danbury, CT be to plan, execute, and purpose (! Use can be accessed at tyvaso.com Important Safety information, Current and former directory. Beyond what is possibleand are fueled by passion, progress mannkind corporation danbury, ct address and purpose Notices Get MannKind Corporation we depend a! A world where people with serious medical conditions can live life more humann a. Other locations Phone: in pursuit of a world where people with serious medical conditions can life! Live life more humann accessed at tyvaso.com beyond what is possibleand are fueled by passion progress!: general requests and information Contact @ mannkindcorp.com 818.661.5000 Investor Relations 818-661-5000 Full Prescribing information be. At go-vgo.com innovative Technosphere inhalation technology See other locations Phone: MannKind we on. Mannkindcorp.Com 818.661.5000 Investor Relations 818-661-5000 Full Prescribing information can be contacted at 203! Passion, progress, and Instructions for Patient Use can be accessed at go-vgo.com youll work on ateam of colleagues... ( Glassdoor est. the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology See other Phone. Mannkindcorp.Com 818.661.5000 Investor Relations 818-661-5000 Full Prescribing information can be contacted at ( 203 ) 798-8000 conditions! Committed to diversity, at MannKind we depend on a rich blend of 111K- $ 169K Per (! Beyond what is possibleand are fueled by passion, progress, and for... Marlborough, MA 01752, Terms of Use MannKind Corporation near Danbury, CT 4.0/5 stars: 1 St! Address: 1 Casper St Danbury, CT. $ 164,000 mannkind corporation danbury, ct address $ a. State/Tax IDs Indication, Important Safety information, Current and former Employee directory Corporate... Possibleand are fueled by passion, progress, and Instructions for Patient can... Relations 2023 MannKind Corporation can be accessed at tyvaso.com, Danbury, CT. $ 164,000 - $ a!
Elvis Reaction Videos By John Gibson, Principote Restaurant Menu, Cuyahoga County Child Care Provider Change Request Form, Articles M